GlassScriptPhysician profile
Kerry R Gomulka
NPI 1639126162
$11,866.47
in general payments reported to CMS, 2019-2025
42 companies · $2,746 in 2025
The $2,746 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,640 · 2022: $1,828 · 2023: $2,966 · 2024: $2,686 · 2025: $2,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,305 · Education: $93.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,304.63 |
| Education | $93.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,142.22 | 2021-2025 | |
| Lilly USA, LLC | $1,481.24 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,446.46 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,003.58 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $800.78 | 2021-2025 | |
| Glaxosmithkline, LLC. | $636.32 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $631.63 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $335.98 | 2023-2025 | Freestyle Libre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $287.05 | 2021-2025 | Xifaxan |
| Amgen INC. | $283.34 | 2021-2025 | Repatha, Otezla, Otezla |
| Axsome Therapeutics, INC. | $276.27 | 2022-2025 | Auvelity, Sunosi |
| Merck Sharp & Dohme LLC | $254.24 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $235.94 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $202.59 | 2021-2022 | |
| Exact Sciences Corporation | $196.18 | 2023-2025 | Cologuard Collection Kit |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Gomulka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.